The Henrietta Lacks Enhancing Cancer Research Act (H.R. 1966), which would direct the U.S. Government Accountability Office (GAO) to study federal policies that directly impact the participation rates of traditionally underrepresented populations in cancer clinical trials nationwide.
The GAO would also recommend potential policy changes across federal agencies that would reduce barriers that currently impede patients from diverse backgrounds from enrolling in clinical trials. Similarly, this bill also needs to move through the Senate, but this is certainly progress.
Read the full press release American Cancer Society Cancer Action Network (ACS CAN) here: